Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary Revance Releases Second Quarter 2018 Results
NEWARK, Calif. --(BUSINESS WIRE)--Aug. 2, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended June 30, 2018 .
View HTML
Toggle Summary Revance Therapeutics to Release Second Quarter 2018 Financial Results on Thursday, August 2, 2018
-Conference Call Scheduled for Thursday, August 2, 2018 at 4:30pm ET - NEWARK, Calif. --(BUSINESS WIRE)--Jul. 19, 2018-- Revance Therapeutics , Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the
View HTML
Toggle Summary Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia
- RT002 Injectable has potential to be first long-acting neuromodulator for treatment of a debilitating involuntary muscle movement disorder - NEWARK, Calif. --(BUSINESS WIRE)--Jun. 21, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in
View HTML
Toggle Summary Revance to Participate in the JMP Securities Life Sciences Conference 2018
NEWARK, Calif. --(BUSINESS WIRE)--Jun. 14, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference
View HTML
Toggle Summary Revance to Participate in Upcoming Investor Conferences
NEWARK, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.
View HTML
Toggle Summary Revance to Participate in the Jefferies 2018 Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Jefferies 2018 Global Healthcare Conference in New York,
View HTML
Toggle Summary Revance Announces Departure of Chief Financial Officer
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance's Chief Financial Officer and Chief Business
View HTML
Toggle Summary Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice
- RT002 achieved high response rate, long-lasting effect across all treatment groups and doses - - RT002 appeared generally safe and well-tolerated through Week 36 - NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for
View HTML
Toggle Summary Revance to Participate in the UBS Global Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the Company will participate in the UBS Global Healthcare Conference in New
View HTML
Toggle Summary Revance Therapeutics Announces Two Recent Additions to Its Management Team
NEWARK, Calif. --(BUSINESS WIRE)-- Revance Therapeutics , Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its management team with the appointments of Conor Gallagher , Ph.D., as Head
View HTML
Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools